Jump to content

Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > mechanism: None

& routes: Oral

& legal: None

Use the filters below to narrow your results.

Aripiprazole (1) · Bupropion / Naltrexone (1) · Butalbital / Acetaminophen / Caffeine (1) · Ciprofloxacin (1) · Gabapentin (1) · Olanzapine (1) · Phentermine (1) · Promethazine (hydrochloride) (1)

Abilify (oral), Abilify Maintena (monthly IM LAI), Aristada (aripiprazole lauroxil IM LAI), Abilify Asimtufii (bi-monthly IM LAI), Abilify MyCite (digital ingestion sensor) (1) · Adipex-P, Lomaira (low-dose); with topiramate as Qsymia (1) · Cipro, Cipro XR, Ciloxan (ophthalmic) (1) · Contrave (US), Mysimba (EU) (1) · Fioricet, Esgic; with codeine as Fioricet with Codeine (Schedule III) (1) · Neurontin (IR), Gralise (ER), Horizant (gabapentin enacarbil ER) (1) · Phenergan, Promethegan (suppositories) (1) · Zyprexa (oral, IM acute), Zyprexa Zydis (ODT), Zyprexa Relprevv (LAI), Lybalvi (with samidorphan) (1)

atypical)]] (1) · [[:Category:Anorectics|Anorectic (appetite suppressant)]] (1) · [[:Category:Anorectics|Anorectic (weight-loss agent)]] (1) · [[:Category:Antibacterials|Antibacterial]] (1) · [[:Category:Anticonvulsants|Anticonvulsant]] (1) · [[:Category:Antidepressants|Antidepressant (bupropion (1) · [[:Category:Antiemetics|Antiemetic]] (1) · [[:Category:Antihistamines|First-generation antihistamine]] (1) · [[:Category:Atypical neuroleptics|Atypical neuroleptic (second-generation)]] (1) · [[:Category:Atypical neuroleptics|Atypical neuroleptic]] (1) · [[:Category:Barbiturates|Barbiturate (butalbital)]] (1) · [[:Category:Fixed-dose_combinations|Fixed-dose combination]] (2) · [[:Category:Fluoroquinolones|Fluoroquinolone antibiotic]] (1) · [[:Category:Gabapentinoids|Gabapentinoid]] (1) · [[:Category:Methylxanthines|Methylxanthine (caffeine)]] (1) · [[:Category:Mood stabilizers|Mood stabilizer]] (2) · [[:Category:Neuroleptics|Neuroleptic]] (2) · [[:Category:Neuropathic pain medicines|Neuropathic pain medicine]] (1) · [[:Category:Non-opioid_analgesics|Non-opioid analgesic (acetaminophen)]] (1) · [[:Category:Opioid_antagonists|Opioid antagonist (naltrexone)]] (1) · [[:Category:Phenothiazines|Phenothiazine]] (1) · [[:Category:Schedule_IV_controlled_substances|Schedule IV controlled substance]] (1) · [[:Category:Sympathomimetics|Sympathomimetic]] (1) · [[:Category:Thienobenzodiazepines|Thienobenzodiazepine]] (1) · [[:Category:Third-generation neuroleptics|Third-generation neuroleptic]] (1)

'"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"' (1) · '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"' (1) · '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (1) · '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"', '"`UNIQ--vote-00000028-QINU`"' (1) · '"`UNIQ--vote-00000932-QINU`"', '"`UNIQ--vote-00000933-QINU`"', '"`UNIQ--vote-00000934-QINU`"', '"`UNIQ--vote-00000935-QINU`"', '"`UNIQ--vote-00000936-QINU`"', '"`UNIQ--vote-00000937-QINU`"' (1) · '"`UNIQ--vote-0000129E-QINU`"' (1) · '"`UNIQ--vote-00001567-QINU`"' (1) · '"`UNIQ--vote-0000159D-QINU`"', '"`UNIQ--vote-0000159E-QINU`"' (1)

1-2 capsules (50 mg butalbital / 325 mg acetaminophen / 40 mg caffeine each) PO every 4 hours as needed; maximum 6 capsules/d (1) · 15-37.5 mg PO once daily before breakfast or 1-2 hours after; Lomaira 8 mg TID (1) · 300 mg PO at bedtime night 1, 300 mg BID day 2, 300 mg TID day 3; titrate to clinical effect, commonly 1800-3600 mg/day divided TID (1) · 500-750 mg PO BID; 400 mg IV q8-12h (1) · Allergy: 25 mg PO BID-QID. Nausea/vomiting: 12.5-25 mg PO/IM/IV/PR every 4-6 hours. Motion sickness: 25 mg PO 30-60 minutes before travel. '''Pediatric <2 years: contraindicated''' (1) · Schizophrenia / acute mania: 5-10 mg PO once daily, target 10-15 mg/day. Acute agitation IM: 10 mg, may repeat in 2 hours. Relprevv LAI: 150-300 mg every 4 weeks after oral overlap (1) · Schizophrenia/bipolar mania: 10-15 mg PO once daily, target 15-30 mg. MDD adjunct: 2-5 mg/day, target 5-15 mg. Pediatric autism irritability: 2 mg, titrate to 5-15 mg. Maintena LAI: 400 mg IM every 4 weeks after oral overlap (1) · Week 1: 1 tablet (8/90 mg) PO morning; week 2: 1 tablet AM + 1 PM; week 3: 2 AM + 1 PM; week 4 onward: 2 AM + 2 PM (32 mg naltrexone / 360 mg bupropion/d) (1)

15, 30, 37.5 mg capsules/tablets; 8 mg Lomaira (1) · 250, 500, 750 mg IR tablets; 500, 1000 mg ER tablets (XR); 250, 500 mg/5 mL oral suspension; 200, 400 mg IV; 0.3% ophthalmic solution and ointment; 0.2% otic (1) · 50/325/40 mg capsules and tablets; oral solution (1) · 8 mg naltrexone / 90 mg bupropion ER tablets (titration-pack design) (1) · Capsules 100, 300, 400 mg; tablets 600, 800 mg; oral solution 250 mg/5 mL; Gralise ER tablets 300, 600 mg (once-daily); Horizant ER tablets 300, 600 mg (gabapentin enacarbil, an inactive parent compound metabolized to gabapentin in vivo) (1) · Tablets 12.5, 25, 50 mg; oral syrup 6.25 mg/5 mL; suppositories 12.5, 25, 50 mg; injection 25 mg/mL and 50 mg/mL (1) · Tablets 2, 5, 10, 15, 20, 30 mg; ODT 10, 15 mg; oral solution 1 mg/mL; acute IM injection 9.75 mg/1.3 mL; Maintena LAI 300, 400 mg monthly; Aristada LAI 441, 662, 882, 1064 mg (4-8 week dosing); Asimtufii bi-monthly (1) · Tablets 2.5, 5, 7.5, 10, 15, 20 mg; ODT (Zydis) 5, 10, 15, 20 mg; acute IM injection 10 mg/vial; Relprevv LAI 210, 300, 405 mg vials (1)

100 mg/day (adult) (1) · 20 mg/day (oral) (1) · 30 mg/day (adult schizophrenia); 15 mg/day (MDD adjunct) (1) · 32 mg naltrexone / 360 mg bupropion per day (1) · 3600 mg/day; off-label doses higher are common but bioavailability saturates well below this (1) · 37.5 mg/d (1) · 6 capsules/d (300 mg butalbital, 1950 mg acetaminophen, 240 mg caffeine) (1) · ~1500 mg/d (oral); 1200 mg/d (IV) (1)

1-2 weeks for neuropathic pain and anxiolytic effect; anticonvulsant effect at therapeutic plasma level (1) · 20 minutes (oral); 5 minutes (IV) (1) · 30-60 minutes (1) · Appetite suppression within hours; weight loss over weeks-months (1) · Hours (1) · Modest appetite suppression within weeks; weight loss over months (1) · Neuroleptic effect emerges over days to weeks; activation symptoms (akathisia, insomnia) often within days (1) · Sedation from first dose; neuroleptic effect emerges over days to weeks (1)

12 hours (BID dosing required) (1) · 24 hours (oral); 2-4 weeks (LAI) (1) · 24 hours (oral); 4-8 weeks (LAI) (1) · 4-6 hours (2) · 8-12 hours (1) · TID dosing for IR; once-daily for ER formulations (1) · ~12-14 hours (1)

12-15 hours'"`UNIQ--ref-00000022-QINU`"' (1) · 21-54 hours'"`UNIQ--ref-00000026-QINU`"' (1) · 4 hours'"`UNIQ--ref-00000938-QINU`"' (1) · 5-7 hours'"`UNIQ--ref-00000029-QINU`"' (1) · Butalbital ~35 hours (long; cumulative effects with frequent use); acetaminophen 1-3 hours; caffeine 3-7 hours'"`UNIQ--ref-0000159F-QINU`"' (1) · Naltrexone ~4 hours (6β-naltrexol metabolite ~13 hours); bupropion ~21 hours'"`UNIQ--ref-00001568-QINU`"' (1) · ~25 hours'"`UNIQ--ref-0000129F-QINU`"' (1) · ~75 hours (long, accumulates over weeks)'"`UNIQ--ref-00000023-QINU`"' (1)

'''Saturable''' via the LAT-1 amino-acid transporter, producing nonlinear pharmacokinetics: ~60% at 300 mg single dose, falling to ~35% at 1200 mg single dose'"`UNIQ--ref-0000002A-QINU`"' (1) · Butalbital well-absorbed; caffeine ~100%; acetaminophen 85-98%'"`UNIQ--ref-000015A0-QINU`"' (1) · High (oral)'"`UNIQ--ref-000012A0-QINU`"' (1) · Naltrexone ~5% (oral, extensive first-pass to 6β-naltrexol); bupropion ER ~87%'"`UNIQ--ref-00001569-QINU`"' (1) · ~25% (oral, with extensive first-pass)'"`UNIQ--ref-00000023-QINU`"' (1) · ~60% (oral); ~100% (IM)'"`UNIQ--ref-00000027-QINU`"' (1) · ~70% (oral; reduced by divalent cations — antacids, iron, calcium, dairy)'"`UNIQ--ref-00000939-QINU`"' (1) · ~87% (oral)'"`UNIQ--ref-00000024-QINU`"' (1)

'''Avoid in pregnancy where alternatives exist''' (animal cartilage toxicity; class-wide concern); use only when benefit clearly outweighs.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Contraindicated in pregnancy (FDA label).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Contraindicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Generally avoided; barbiturate exposure in late pregnancy can produce neonatal withdrawal and respiratory depression.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Limited human data; signal for neonatal extrapyramidal symptoms and withdrawal with third-trimester exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Limited human data; some signal for cardiac malformations and developmental delay but confounded by maternal disease and polytherapy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Older agent with substantial use experience, including in hyperemesis gravidarum; broadly reassuring observational data'"`UNIQ--ref-00000024-QINU`"' (1) · Signal for gestational diabetes and metabolic syndrome with maternal exposure; the metabolic load can be substantial during pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

Showing below up to 8 results in range #1 to #8.

A

Aripiprazole

C

F

Fioricet

G

Gabapentin

O

Olanzapine

P

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"